583 related articles for article (PubMed ID: 33963182)
1. Co-evolution of tumor and immune cells during progression of multiple myeloma.
Liu R; Gao Q; Foltz SM; Fowles JS; Yao L; Wang JT; Cao S; Sun H; Wendl MC; Sethuraman S; Weerasinghe A; Rettig MP; Storrs EP; Yoon CJ; Wyczalkowski MA; McMichael JF; Kohnen DR; King J; Goldsmith SR; O'Neal J; Fulton RS; Fronick CC; Ley TJ; Jayasinghe RG; Fiala MA; Oh ST; DiPersio JF; Vij R; Ding L
Nat Commun; 2021 May; 12(1):2559. PubMed ID: 33963182
[TBL] [Abstract][Full Text] [Related]
2. The multiple myeloma microenvironment is defined by an inflammatory stromal cell landscape.
de Jong MME; Kellermayer Z; Papazian N; Tahri S; Hofste Op Bruinink D; Hoogenboezem R; Sanders MA; van de Woestijne PC; Bos PK; Khandanpour C; Vermeulen J; Moreau P; van Duin M; Broijl A; Sonneveld P; Cupedo T
Nat Immunol; 2021 Jun; 22(6):769-780. PubMed ID: 34017122
[TBL] [Abstract][Full Text] [Related]
3. Alterations in the Transcriptional Programs of Myeloma Cells and the Microenvironment during Extramedullary Progression Affect Proliferation and Immune Evasion.
Ryu D; Kim SJ; Hong Y; Jo A; Kim N; Kim HJ; Lee HO; Kim K; Park WY
Clin Cancer Res; 2020 Feb; 26(4):935-944. PubMed ID: 31558476
[TBL] [Abstract][Full Text] [Related]
4. Clonal Expansion and Interrelatedness of Distinct B-Lineage Compartments in Multiple Myeloma Bone Marrow.
Hansmann L; Han A; Penter L; Liedtke M; Davis MM
Cancer Immunol Res; 2017 Sep; 5(9):744-754. PubMed ID: 28768640
[TBL] [Abstract][Full Text] [Related]
5. Myeloma Propagating Cells, Drug Resistance and Relapse.
Karadimitris A; Chaidos A; Caputo V; Goudevenou K; Ponnusamy K; Xiao X
Stem Cells; 2015 Nov; 33(11):3205-11. PubMed ID: 26302895
[TBL] [Abstract][Full Text] [Related]
6. Multiple myeloma clonal evolution in homogeneously treated patients.
Corre J; Cleynen A; Robiou du Pont S; Buisson L; Bolli N; Attal M; Munshi N; Avet-Loiseau H
Leukemia; 2018 Dec; 32(12):2636-2647. PubMed ID: 29895955
[TBL] [Abstract][Full Text] [Related]
7. Progression signature underlies clonal evolution and dissemination of multiple myeloma.
Shen YJ; Mishima Y; Shi J; Sklavenitis-Pistofidis R; Redd RA; Moschetta M; Manier S; Roccaro AM; Sacco A; Tai YT; Mercier F; Kawano Y; Su NK; Berrios B; Doench JG; Root DE; Michor F; Scadden DT; Ghobrial IM
Blood; 2021 Apr; 137(17):2360-2372. PubMed ID: 33150374
[TBL] [Abstract][Full Text] [Related]
8. Hierarchy of mono- and biallelic
Munawar U; Rasche L; Müller N; Vogt C; Da-Via M; Haertle L; Arampatzi P; Dietrich S; Roth M; Garitano-Trojaola A; Steinhardt MJ; Strifler S; Gallardo M; Martinez-Lopez J; Bargou RC; Heckel T; Einsele H; Stühmer T; Kortüm KM; Barrio S
Blood; 2019 Sep; 134(10):836-840. PubMed ID: 31340981
[No Abstract] [Full Text] [Related]
9. Cell autonomous and microenvironmental regulation of tumor progression in precursor states of multiple myeloma.
Manier S; Kawano Y; Bianchi G; Roccaro AM; Ghobrial IM
Curr Opin Hematol; 2016 Jul; 23(4):426-33. PubMed ID: 27101529
[TBL] [Abstract][Full Text] [Related]
10. Myeloid transformation of plasma cell myeloma: molecular evidence of clonal evolution revealed by next generation sequencing.
Gralewski JH; Post GR; van Rhee F; Yuan Y
Diagn Pathol; 2018 Feb; 13(1):15. PubMed ID: 29463311
[TBL] [Abstract][Full Text] [Related]
11. [Chromosomal abnormalities and clonal evolution in multiple myeloma].
Ishida T
Rinsho Ketsueki; 2014 Oct; 55(10):2036-45. PubMed ID: 25297769
[No Abstract] [Full Text] [Related]
12. Comprehensive Characterization of the Multiple Myeloma Immune Microenvironment Using Integrated scRNA-seq, CyTOF, and CITE-seq Analysis.
Yao L; Jayasinghe RG; Lee BH; Bhasin SS; Pilcher W; Doxie DB; Gonzalez-Kozlova E; Dasari S; Fiala MA; Pita-Juarez Y; Strausbauch M; Kelly G; Thomas BE; Kumar SK; Cho HJ; Anderson E; Wendl MC; Dawson T; D'souza D; Oh ST; Cheloni G; Li Y; DiPersio JF; Rahman AH; Dhodapkar KM; Kim-Schulze S; Vij R; Vlachos IS; Mehr S; Hamilton M; Auclair D; Kourelis T; Avigan D; Dhodapkar MV; Gnjatic S; Bhasin MK; Ding L
Cancer Res Commun; 2022 Oct; 2(10):1255-1265. PubMed ID: 36969740
[TBL] [Abstract][Full Text] [Related]
13. Subclone-specific microenvironmental impact and drug response in refractory multiple myeloma revealed by single-cell transcriptomics.
Tirier SM; Mallm JP; Steiger S; Poos AM; Awwad MHS; Giesen N; Casiraghi N; Susak H; Bauer K; Baumann A; John L; Seckinger A; Hose D; Müller-Tidow C; Goldschmidt H; Stegle O; Hundemer M; Weinhold N; Raab MS; Rippe K
Nat Commun; 2021 Nov; 12(1):6960. PubMed ID: 34845188
[TBL] [Abstract][Full Text] [Related]
14. 1q amplification and PHF19 expressing high-risk cells are associated with relapsed/refractory multiple myeloma.
Johnson TS; Sudha P; Liu E; Becker N; Robertson S; Blaney P; Morgan G; Chopra VS; Dos Santos C; Nixon M; Huang K; Suvannasankha A; Zaid MA; Abonour R; Walker BA
Nat Commun; 2024 May; 15(1):4144. PubMed ID: 38755140
[TBL] [Abstract][Full Text] [Related]
15. The Role of Marrow Microenvironment in the Growth and Development of Malignant Plasma Cells in Multiple Myeloma.
Giannakoulas N; Ntanasis-Stathopoulos I; Terpos E
Int J Mol Sci; 2021 Apr; 22(9):. PubMed ID: 33923357
[TBL] [Abstract][Full Text] [Related]
16. Whole-genome sequencing of multiple myeloma from diagnosis to plasma cell leukemia reveals genomic initiating events, evolution, and clonal tides.
Egan JB; Shi CX; Tembe W; Christoforides A; Kurdoglu A; Sinari S; Middha S; Asmann Y; Schmidt J; Braggio E; Keats JJ; Fonseca R; Bergsagel PL; Craig DW; Carpten JD; Stewart AK
Blood; 2012 Aug; 120(5):1060-6. PubMed ID: 22529291
[TBL] [Abstract][Full Text] [Related]
17. Disease progression in patients with multiple myeloma is associated with a concurrent alteration in the expression of both oncogenes and tumour suppressor genes and can be monitored by the oncoprotein phenotype.
Pope B; Brown R; Luo XF; Gibson J; Joshua D
Leuk Lymphoma; 1997 May; 25(5-6):545-54. PubMed ID: 9250826
[TBL] [Abstract][Full Text] [Related]
18. Malignant clonal evolution drives multiple myeloma cellular ecological diversity and microenvironment reprogramming.
Liang Y; He H; Wang W; Wang H; Mo S; Fu R; Liu X; Song Q; Xia Z; Wang L
Mol Cancer; 2022 Sep; 21(1):182. PubMed ID: 36131282
[TBL] [Abstract][Full Text] [Related]
19. The role of toll-like receptor mediated signalling in the pathogenesis of multiple myeloma.
Abdi J; Engels F; Garssen J; Redegeld F
Crit Rev Oncol Hematol; 2011 Nov; 80(2):225-40. PubMed ID: 21236697
[TBL] [Abstract][Full Text] [Related]
20. Improved prognostication of glioblastoma beyond molecular subtyping by transcriptional profiling of the tumor microenvironment.
Jeanmougin M; Håvik AB; Cekaite L; Brandal P; Sveen A; Meling TR; Ågesen TH; Scheie D; Heim S; Lothe RA; Lind GE
Mol Oncol; 2020 May; 14(5):1016-1027. PubMed ID: 32171051
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
